Beijing Biostar Pharms Co Ltd
HKSE: 2563.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Rongguo Qiu
- Employees
- 147
- Headquarters
- Beijing, China
- IPO year
- 2024
- Market cap
- HK$962.2M
- Website
- http://www.biostar-pharm.com
Loading 2563…
Loading profile data…Frequently asked questions about 2563
What does Beijing Biostar Pharms Co Ltd (2563.HK) do?
Beijing Biostar Pharmaceuticals Co. Ltd. engages in the provision of treatment for tumor. The company focuses on the development of new anti-cancer drugs with independent intellectual property rights. Its product Utidelone injection is the new-generation microtubule inhibitor produced by microbial fermentation process. The company was founded by...
Where does 2563.HK trade?
Beijing Biostar Pharms Co Ltd (2563.HK) trades on the Hong Kong Stock Exchange.
What sector is 2563.HK in?
Beijing Biostar Pharms Co Ltd (2563.HK) operates in the Healthcare sector, specifically in the Drug Manufacturers - General industry.
Who is the CEO of Beijing Biostar Pharms Co Ltd?
Rongguo Qiu is the chief executive officer of Beijing Biostar Pharms Co Ltd (2563.HK).
Where is Beijing Biostar Pharms Co Ltd headquartered?
Beijing Biostar Pharms Co Ltd is headquartered in China.
Does 2563.HK pay a dividend?
Beijing Biostar Pharms Co Ltd (2563.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 2563.HK go public?
Beijing Biostar Pharms Co Ltd (2563.HK) completed its initial public offering in 2024.